[New developments in neonatal screening].

NEW DEVELOPMENTS IN NEONATAL SCREENING. The French national newborn screening program (NBS) celebrated its 50th anniversary in 2022. A few drops of blood are drawn between 48 and 72 hours of life for each newborn on a filter paper and entrusted to a Regional Center for Newborn Screening, which analyses it diligently. When the result is beyond a threshold, the baby and its parents are summoned to a specialized paediatric department. If the suspected disease is confirmed, specific care can be started in time to avoid or limit a disability. Each year, nearly 1.000 sick children are diagnosed by NBS in France, and treated in a specialized hospital team. The 2018 National Rare Disease Plan has relaunched the NBS process. Until then, 7 diseases whose hearing loss were detected. Since then, 7 other diseases have been added to the program, and others were recommended or are being assessed, opening a new page in the history of NBS in France.
Competing Interests: D. Cheillan déclare des interventions ponctuelles pour Orchard Therapeutics. M. Polak, T. Nguyen-Khoa, S. Lachambre, P de Lonlay, A. Khemiri et S. Courapied déclarent n’avoir aucun lien d’intérêts. J.-B. Arnoux déclare des interventions ponctuelles pour Ultragenyx, Rezolute, Immedica et Biomarin, et avoir été pris en charge, à l’occasion de déplacement pour congrès, par Immedica et Biomarin.